| Literature DB >> 27064843 |
Seungjoo Lee1, Go Woon Jun2, Sang Beom Jeon3, Chang Jin Kim1, Jeong Hoon Kim1.
Abstract
Severe paroxysmal sympathetic overactivity occurs in a subgroup of patients with acquired brain injuries including traumatic brain injury, hypoxia, infection and tumor-related complications. This condition is characterized by sudden increase of heart rate, respiratory rate, blood pressure, body temperature and excessive diaphoresis. The episodes may be induced by external stimulation or may occur spontaneously. Frequent occurrence of this condition could result in secondary morbidities, therefore, should be diagnosed and managed insightfully. These symptoms could be confused with seizures or other medical conditions, leading to unnecessary treatment. Despite clinical significance of paroxysmal sympathetic hyperactivity (PSH), brain tumor-induced PSH has not been studied nearly. In this report, two cases of the PSH in patients with brainstem-compressing benign tumors were introduced. The most useful pharmacologic agents were opioid (e.g., fentanyl patch) in preventing PSH attack, and nonselective β-blocker (e.g., propranolol) in relieving the symptoms. Clinical experiences of the rare cases of benign tumor-induced PSH can be helpful as an essential basis for further research.Entities:
Keywords: Brain tumor; Brainstem; Opioid; Paroxysmal sympathetic hyperactivity
Year: 2016 PMID: 27064843 PMCID: PMC4792828 DOI: 10.1186/s40064-016-1898-x
Source DB: PubMed Journal: Springerplus ISSN: 2193-1801
Fig. 1a. Preoperative radiologic imaging of patient 1 with PSH. Huge size (8.1 cm) extraaxial calcified mass over left middle cranial fossa and posterior cranial fossa is compressing brainstem. This mass originates from petrosal apex and displaces midbrain, pons, and middle cerebellar peduncle to right side. (Clockwise direction; T2WI coronal, T1W enhance coronal, CT with enhance, T1W enhance axial). b. Postoperative (POD 20) CT scan showing residual calcified mass adjacent to brainstem and hemorrhage, edema in brainstem
Fig. 2Histopathology of patient 1’s specimen (hematoxylin and eosin stain). Distinctly, there are abundant fibrous and chondroid matrix with formation of pink homogenous osteoid (Blue arrow, in a, b). Some areas of the tumor show obvious cartilaginous differentiation with well-formed hyaline cartilage (black arrow in a). Most areas of the tumor consist of cellular proliferation of small rounded chondrocytes (blue arrow in d). These cells are focally arranged in cords and trabeculae (c). Based on these findings, patient was diagnosed chondrosarcoma. (a, c: 40×, b, d: 100×)
Fig. 3Vital signs of patients with PSH attack. Asterisks (*) indicate outlier points above normal limit. Gradations on X axis indicate 30 min intervals
Fig. 4a. Preoperative MRI of patient 2 showing PSH. A 7.7 cm-sized homogenous enhancing cystic and solid extraaxial mass originates form jugular foramen. This mass extends from retroclival area to posterior fossa compressing brainstem. (Clockwise direction; T2WI coronal, T1W enhance coronal, T1 W enhance axial, 3D FLAIR). b. Immediate postoperative CT scan demonstrating focal hemorrhage and edema in compressed brainstem. c. Postoperative CT scan (POD 14) when the PSH occurred
Fig. 5Histopathology of patient 2’s specimen (H&E stain). a. Biphasic pattern with cellar Antoni A (single asterisk) and hypocellular Antoni B (dual asterisk) areas. b. Schwann cell nuclei forming palisades focally and showing compact fasciles of elongated tumor cells with nuclear polymorphism. Based on these findings, patient was diagnosed schwannoma. (a: 40×, b: 100×)
Diagnostic criteria of PSH: transient presence of four of the six criteria without other potential causes
| Clinical features | |
|---|---|
| Fever | Body temperature > 38.3 °C |
| Tachycardia | Heart rate > 120 beats/min or >100 beats/min with β-blocker |
| Hypertension | Systolic blood pressure > 160 mmHg or pulse pressure > 80 mmHg |
| Tachypnea | Respiratory rate > 30 breaths/min |
| Excessive diaphoresis | |
| Extensor posturing or severe dystonia |
Summary of commonly used pharmacologic agents in PSH
| Drug | Dose | Mechanism | Adverse effect | Our experience | Special points |
|---|---|---|---|---|---|
| Opioids | 2–8 mg (IV morphine) | Reducing pain response, blunting sympathetic activity | Respiratory depression, constipation, ileus hypotension over-sedation | Most effective in preventing PSH event | Need adequate dose titration |
| Bromocriptine | 1.25 mg/bid/day (PO) | D2 agonist | Confusion, dyskinesia, hypotension | Not used | Titrate up to 10–40 mg/day |
| Baclofen | 5 mg/tid/day (PO) | GABAB agonist | Muscle weakness, sedation, liver enzyme elevation, bronchial hyperactivity | Not effective | PO agent is not effective |
| Propranolol | 20–60 mg/qid/day (PO) | Nonselective β-blocker | Negative inotropic effect, bronchospasm, hypoglycemia | Effective in decreasing BP and HR during PSH attack | Contraindication in COPD, AV block, Heart failure |
| Benzodiazepines | Midazolam 1–2 mg IV | GABAA agonist | Respiratory depression, hypotension, over-sedation | Not effective | Diazepam may be preferred in PSH |
| Dantrolene | 0.25–2 mg/kg/bid/Day (IV) | Muscle excitation–contraction dissociation by blocking Ca2 + release from sarcoplasmic reticulum | Fatal hepatotoxicity, respiratory depression | Not used | Effective for amelioration of dystonic posturing |
| Gabapentin | 300–900 mg/day (PO) | Block α2δ subunit of voltage-gated Ca2 + channel, inhibiting neurotransmitter release in CNS | Sedation, lethargy | Not used | Titrate up to 3600–4800 mg/day |